Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company") is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration (FDA) to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. The FDA has approved the Company's Investigational New Drug (IND) application and has approved the Company's commencement of a clinical program titled "A Phase 1/2, Evaluation of the Safety and Efficacy of RP-323 in Combination with all-trans-Retinoic Acid, Sodium Butyrate, and 1α, 25-dihydroxyvitamin D₃ in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)". This approval gives the Company an immediate go ahead to start patient enrollment for a Phase 1/2 study using Rich Pharmaceuticals' lead compound RP-323 in clinical trials.

"This is a very exciting time at Rich Pharmaceuticals. I am pleased to announce that we have reached our most significant milestone to date," said Chief Executive Officer, Ben Chang. "Our team is enthusiastic with this development and we look forward to considerable advancement as we plan to begin clinical trials in the upcoming year."